Emerald Health Therapeutics Named as #1 2018 TSX Venture 50™ Performer
February 22 2018 - 8:00AM
Emerald Health Therapeutics, Inc. (TSX-V:EMH) (OTCQX:EMHTF)
("Emerald") has achieved the #1 ranking in the 2018 TSX Venture 50™
for the clean technology & life science sector and is
recognized as a top performing company for the second consecutive
year. The TSX Venture 50™ is the TSX Venture Exchange’s annual
ranking of Canada’s top 50 emerging publicly traded
companies.
“Emerald, like all the companies in the TSX
Venture 50™ and in the rapidly growing cannabis sector, aspires to
build a growing and differentiated business that will provide
notable value to shareholders. In achieving #1 status in our sector
in 2018, I extend a big thank you to our entire team for their
effort and our shareholders for their support,” said Chris Wagner,
CEO of Emerald. “We are executing very well on our major production
expansion projects, are well-financed, and are advancing unique
product innovation and marketing initiatives. We believe these
factors strongly position Emerald for the anticipated legal
adult-use cannabis market in Canada and for emerging international
opportunities.”
Winner selections are based on a formula with
equal weighting given to share price appreciation, market
capitalization growth, and trading volume for the year ending
December 31, 2017. The TSX Venture 50™ acknowledges the top 10
performing companies listed on the TSX Venture Exchange in five
industry sectors: mining, oil & gas, clean technology &
life sciences, diversified industries, and technology.
The TSXV created a video profile on Emerald and
other 2018 TSX Venture 50™ winners, available at
www.tsx.com/venture50.
Earlier this month Emerald announced that it had
been upgraded to Tier 1 on the the TSX Venture Exchange. This
status was based on standards regarding historical financial
performance, stage of development, and financial resources. Tier 1
is the highest tier of the TSX-V and is reserved for more advanced
issuers with greater financial resources.
Emerald Health Therapeutics, Inc.
Emerald Health Therapeutics, Inc. (TSX-V:EMH) (OTCQX:EMHTF)
operates through Emerald Health Botanicals Inc. ("Botanicals"), a
wholly owned subsidiary and Licensed Producer under Canada’s Access
to Cannabis for Medical Purposes Regulations. Through Botanicals,
Emerald is authorized to produce and sell dried medical cannabis
flower and medical cannabis oil. It currently operates an indoor
facility in Victoria, BC, and is building a 500,000 s.f. greenhouse
on 32 acres in Metro Vancouver, with expansion potential to 1
million s.f. to serve the anticipated legal Canadian adult-use
cannabis market starting in 2018. Emerald also owns 50% of Pure
Sunfarms Inc., a partnership with Village Farms International Inc.
that is converting an existing 1.1 million s.f. greenhouse in
Delta, BC from growing tomatoes to growing cannabis. Emerald’s team
is highly experienced in life sciences, product development and
large-scale agribusiness. Emerald is part of the Emerald Health
group, which is broadly focused on developing pharmaceutical,
botanical and nutraceutical products that may provide wellness and
medical benefits by interacting with the human body’s
endocannabinoid system.Please visit www.emeraldhealth.ca for more
information or contact:
Robert Hill, CFO(800) 757 3536 Ext.
#722invest@emeraldhealth.ca
Cautionary Statements Regarding Forward Looking
Information
Certain statements in this press release constitute
forward-looking statements, within the meaning of applicable
securities laws. All statements that are not historical facts,
including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements".
We caution you that such "forward-looking statements" involve
known and unknown risks and uncertainties that could cause actual
and future events to differ materially from those anticipated in
such statements. Forward-looking statements include, but are not
limited to exercise of the Investor’s existing warrants; the
development, expansion and conversion of greenhouse facilities; and
the starting of adult-use cannabis market in 2018.
Emerald Health Therapeutics Inc. does not intend, and does not
assume any obligation, to update these forward-looking statements
except as required by law. These forward-looking statements involve
risks and uncertainties relating to, among other things, the
ability of the Company to negotiate and complete future funding
transactions; variations in market conditions; and other risk
factors described in the Prospectus and the Company's other filings
with the applicable Canadian securities regulators, which may be
viewed at www.sedar.com. Actual results may differ materially
from those expressed or implied by such forward-looking
statements.
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Sep 2023 to Sep 2024